Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.35T
Market cap1.35T
Price-Earnings ratio
47.42
Price-Earnings ratio47.42
Dividend yield
0.46%
Dividend yield0.46%
Average volume
3.23M
Average volume3.23M
High today
$1,475.25
High today$1,475.25
Low today
$1,427.66
Low today$1,427.66
Open price
$1,455.92
Open price$1,455.92
Volume
3.07M
Volume3.07M
52 Week high
$1,475.25
52 Week high$1,475.25
52 Week low
$850.51
52 Week low$850.51

Stock Snapshot

With a market cap of 1.35T, Eli Lilly(LLY) trades at $1,435.00. The stock has a price-to-earnings ratio of 47.42 and currently yields dividends of 0.46%.

During the trading session on 2026-11-16, Eli Lilly(LLY) shares reached a daily high of $1,475.25 and a low of $1,427.66. At a current price of $1,435.00, the stock is +0.5% higher than the low and still -2.7% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 3.07M, versus its average volume of 3.23M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

LLY News

Simply Wall St 2h
Eli Lilly Agrees $1.5 Billion Rare Blood Cancer Acquisition

Eli Lilly (NYSE:LLY) agreed to acquire privately held Calytrix Bio in a deal valued at up to US$1.5b. The transaction brings Calytrix Bio's rare blood cancer p...

Eli Lilly Agrees $1.5 Billion Rare Blood Cancer Acquisition
The Motley Fool 2h
Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head

The past decade has been eventful for Eli Lilly (LLY +0.05%). The company made significant breakthroughs in diabetes and weight loss, which helped drive its mar...

Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head
TipRanks 3h
M&A News: Eli Lilly Buys Calytrix Bio for $1.5 Billion

Eli Lilly (LLY) is acquiring privately held Calytrix Bio in a deal that’s valued at up to $1.5 billion....

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

More LLY News

Seeking Alpha 3h
Eli Lilly in up to $1.5B deal to acquire Calytrix Bio

M&A Eli Lilly in up to $1.5B deal to acquire Calytrix Bio Nov 16, 2026, 1:16 PM ET Eli Lilly and Company (LLY) Stock JPM By : Jonathan Block, SA News Editor Eli...

Eli Lilly in up to $1.5B deal to acquire Calytrix Bio
Benzinga 5h
Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion As ObesityWeek Data Roll In

Eli Lilly and Co. (NYSE:LLY) on Monday agreed to acquire Calytrix Bio Inc. for up to $1.5 billion in cash, as the drugmaker also presents new cardiometabolic da...

Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion As ObesityWeek Data Roll In
TipRanks 8h
Eli Lilly to acquire Calytrix Bio for up to $1.5B in cash

Calytrix Bio, a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms, announced a definitive agreemen...

TipRanks 11h
Eli Lilly price target raised to $1,550 from $1,400 at Barclays

Barclays analyst Emily Field raised the firm’s price target on Eli Lilly (LLY) to $1,550 from $1,400 and keeps an Overweight rating on the shares post the Q3 re...

TipRanks 1d
Eli Lilly to present new data across portfolio at ObesityWeek 2026

Eli Lilly (LLY) and Company will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Wash...

Simply Wall St 2d
Learn Why The Bull Case For Eli Lilly Could Change Following Obesity Drug Trial Results

Eli Lilly is leaning into its obesity and cardiometabolic franchise, reporting detailed Phase 3 results for Foundayo and Zepbound across conditions like obstruc...

Learn Why The Bull Case For Eli Lilly Could Change Following Obesity Drug Trial Results
Simply Wall St 3d
Eli Lilly Faces New Vision Loss Lawsuits As Pipeline Milestones Keep Coming

Eli Lilly (NYSE:LLY) faces new lawsuits alleging its GLP-1 drug Mounjaro causes irreversible vision loss linked to NAION. Regulators in several countries issue...

Eli Lilly Faces New Vision Loss Lawsuits As Pipeline Milestones Keep Coming

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.